FDA Approves Lilly’s Strattera, First Nonstimulant ADHD Treatment

January 27, 2003 FDA Approves Lilly's Strattera, First Nonstimulant ADHD Treatment On November 26, 2002, the U.S. Food and Drug Administration (FDA) approved Strattera (atomoxetine HCl) produced by Eli Lilly & Company, the first nonstimulant approved for the treatment of Attention-Deficit/Hyperactivity Disorder.  According to a January 14, 2003, announcement by Lilly, Strattera is now available by prescription in pharmacies nationwide. Strattera, a selective norepinephrine reuptake inhibitor, works differently than any older FDA-approved treatments for the disorder, all of which are stimulants. Strattera comes in a capsule and can be taken once or twice a day . . .